Brief: Atea Pharmaceuticals Announces Full Results From Phase 2 Study Of Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus (HCV) Presented At EASL Congress 2025
07/05/2025 12:12
May 7 (Reuters) - Atea Pharmaceuticals Inc AVIR.O: ATEA PHARMACEUTICALS ANNOUNCES FULL RESULTS FROM PHASE 2 STUDY OF REGIMEN OF BEMNIFOSBUVIR AND RUZASVIR FOR TREATMENT OF HEPATITIS C VIRUS (HCV) PRESENTED AT EASL CONGRESS 2025 Source text: ID:nGNX5TgVm1 Further company coverage: AVIR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM